Corcept Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Corcept Therapeutics kazanç ve gelirin sırasıyla yıllık 45.6% ve 18.9% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 43.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 4.8% olacağı tahmin edilmektedir.

Anahtar bilgiler

45.6%

Kazanç büyüme oranı

43.66%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	11.2%
Gelir büyüme oranı	18.9%
Gelecekteki özkaynak getirisi	4.76%
Analist kapsamı	Low
Son güncelleme	30 Mar 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug

Jan 04

The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56%

Jan 01

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable

Oct 07

Corcept Therapeutics Incorporated (NASDAQ:CORT) Looks Just Right With A 35% Price Jump

Apr 08

We Think Corcept Therapeutics' (NASDAQ:CORT) Solid Earnings Are Understated

Mar 05

Corcept Therapeutics Incorporated (NASDAQ:CORT) Looks Just Right With A 39% Price Jump

Jan 31

Here's Why Corcept Therapeutics (NASDAQ:CORT) Has Caught The Eye Of Investors

Jan 01

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:CORT - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	1,366	494	355	487	5
12/31/2027	1,164	221	159	285	5
12/31/2026	933	40	108	108	5
12/31/2025	761	98	142	142	N/A
9/30/2025	741	105	163	163	N/A
6/30/2025	716	132	180	182	N/A
3/31/2025	685	133	177	179	N/A
12/31/2024	675	140	196	198	N/A
9/30/2024	629	140	142	144	N/A
6/30/2024	570	125	123	124	N/A
3/31/2024	524	117	125	125	N/A
12/31/2023	482	105	127	127	N/A
9/30/2023	450	91	154	155	N/A
6/30/2023	428	94	135	135	N/A
3/31/2023	414	94	111	111	N/A
12/31/2022	402	101	120	120	N/A
9/30/2022	398	117	136	136	N/A
6/30/2022	392	113	151	151	N/A
3/31/2022	380	112	177	178	N/A
12/31/2021	366	113	167	168	N/A
9/30/2021	353	106	153	154	N/A
6/30/2021	343	98	134	135	N/A
3/31/2021	340	99	143	144	N/A
12/31/2020	354	106	151	152	N/A
9/30/2020	356	109	164	165	N/A
6/30/2020	351	114	173	173	N/A
3/31/2020	335	106	145	146	N/A
12/31/2019	306	94	135	136	N/A
9/30/2019	285	87	N/A	109	N/A
6/30/2019	268	78	N/A	115	N/A
3/31/2019	258	76	N/A	105	N/A
12/31/2018	251	75	N/A	116	N/A
9/30/2018	238	152	N/A	119	N/A
6/30/2018	216	148	N/A	85	N/A
3/31/2018	189	142	N/A	86	N/A
12/31/2017	159	129	N/A	61	N/A
9/30/2017	130	35	N/A	41	N/A
6/30/2017	109	24	N/A	39	N/A
3/31/2017	93	13	N/A	25	N/A
12/31/2016	81	8	N/A	18	N/A
9/30/2016	72	5	N/A	18	N/A
6/30/2016	64	1	N/A	10	N/A
3/31/2016	56	-2	N/A	8	N/A
12/31/2015	50	-6	N/A	3	N/A
9/30/2015	44	-11	N/A	-2	N/A
6/30/2015	38	-17	N/A	-9	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CORT 'nin tahmini kazanç büyümesi (yıllık 45.6% ) tasarruf oranının ( 3.4% ) üzerindedir.

Kazançlar ve Piyasa: CORT şirketinin kazançlarının (yıllık 45.6% ) US pazarından (yıllık 15.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: CORT şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: CORT şirketinin gelirinin (yıllık 18.9% ) US pazarından (yıllık 10.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: CORT şirketinin gelirinin (yıllık 18.9% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CORT 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 4.8 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/04/09 16:20
Gün Sonu Hisse Fiyatı	2026/04/09 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Corcept Therapeutics Incorporated 18 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Tazeen Ahmad	BofA Global Research
Debjit Chattopadhyay	Brean Capital Historical (Janney Montgomery)
David Buck	B. Riley Securities, Inc.

Corcept Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates fall by 11%

Corcept Therapeutics Incorporated Provides Revenue Guidance for the Full Year 2026

Price target decreased by 7.7% to US$84.00

Consensus EPS estimates fall by 11%

Price target decreased by 18% to US$110

Corcept Therapeutics Incorporated Modifies Revenue Guidance for the Full Year 2025

Recent updates

Chief Development Officer notifies of intention to sell stock

Corcept Therapeutics Incorporated Presents Data From Momentum Trial At American College Of Cardiology Annual Scientific Session

Co-Founder notifies of intention to sell stock

Corcept Therapeutics Incorporated Receives FDA Approval For Lifyorli (Relacorilant) Plus Nab-Paclitaxel For Platinum-Resistant Ovarian Cancer

Investor sentiment improves as stock rises 22%

Chief Development Officer notifies of intention to sell stock

Consensus EPS estimates fall by 11%

Full year 2025 earnings: EPS and revenues miss analyst expectations

Corcept Therapeutics Incorporated Provides Revenue Guidance for the Full Year 2026

Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated to Report Q4, 2025 Results on Feb 24, 2026

Price target decreased by 7.7% to US$84.00

Independent Director exercised options to buy US$6.2m worth of stock.

Investor sentiment improves as stock rises 17%

Corcept Therapeutics Incorporated Announces Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Chief Development Officer notifies of intention to sell stock

Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug

Consensus EPS estimates fall by 11%

The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56%

Corcept Receives Complete Response Letter for Relacorilant as A Treatment for Patients with Hypercortisolism

New minor risk - Share price stability

Price target decreased by 18% to US$110

Investor sentiment deteriorates as stock falls 16%

Co-Founder exercised options and sold US$24m worth of stock

Co-Founder notifies of intention to sell stock

Now 21% overvalued after recent price rise

Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Corcept Therapeutics Incorporated Modifies Revenue Guidance for the Full Year 2025

Co-Founder notifies of intention to sell stock

Corcept Therapeutics Incorporated to Report Q3, 2025 Results on Nov 04, 2025

Corcept Therapeutics Incorporated Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment

Corcept Therapeutics Incorporated Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as A Treatment for Patients with Platinum-Resistant Ovarian Cancer

Investor sentiment deteriorates as stock falls 16%

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable

Corcept Therapeutics Incorporated Announces Resignation of Gillian Cannon from the Board, Effective as of October 10, 2025

Co-Founder notifies of intention to sell stock

Investor sentiment improves as stock rises 16%

FDA Files Corcept Therapeutics Incorporated's New Drug Application for Relacorilant as A Treatment for Patients with Platinum-Resistant Ovarian Cancer

Co-Founder notifies of intention to sell stock

Consensus EPS estimates fall by 22%

President of Endocrinology notifies of intention to sell stock

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Corcept Therapeutics Incorporated to Report Q2, 2025 Results on Jul 31, 2025

Co-Founder notifies of intention to sell stock

Corcept Therapeutics Incorporated Submits New Drug Application for Relacorilant as A Treatment for Patients with Platinum-Resistant Ovarian Cancer

New minor risk - Insider selling

Chief Development Officer notifies of intention to sell stock

Corcept Therapeutics Incorporated(NasdaqCM:CORT) dropped from Russell 2000 Defensive Index

Corcept Therapeutics Incorporated Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association's 85th Scientific Sessions with Simultaneous Publication in Diabetes Care

Chief Development Officer exercised options and sold US$1.0m worth of stock

Corcept Therapeutics Incorporated Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting

Co-Founder notifies of intention to sell stock

Corcept Therapeutics Incorporated Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet

Consensus EPS estimates fall by 19%

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Corcept Therapeutics Incorporated Reiterates Revenue Guidance for the Full Year 2025

President of Endocrinology notifies of intention to sell stock

Corcept Therapeutics Incorporated to Report Q1, 2025 Results on May 05, 2025

Corcept Therapeutics Incorporated, Annual General Meeting, Jun 10, 2025

Investor sentiment improves as stock rises 15%

Corcept Therapeutics Incorporated Announces the Publication of Findings from the Prevalence Phase of the Catalyst Trial in Diabetes Care

Corcept Therapeutics Incorporated Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer

Corcept Therapeutics Incorporated (NASDAQ:CORT) Looks Just Right With A 35% Price Jump

Investor sentiment improves as stock rises 40%

Consensus EPS estimates fall by 11%

Chief Accounting & Technology Officer notifies of intention to sell stock

New major risk - Share price stability

Corcept Therapeutics Announces Primary Endpoint Met in Corcept’S Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Price target increased by 10% to US$107